Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Grebien, Florian; Hantschel, Oliver; Wojcik, John; Kaupe, Ines; Kovacic, Boris; Wyrzucki, Arkadiusz M.; Gish, Gerald D.; Cerny-Reiterer, Sabine; Koide, Akiko; Beug, Hartmut; Pawson, Tony; Valent, Peter; Koide, Shohei; Superti-Furga, Giulio

doi:10.1016/j.cell.2011.08.046

Title: Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Full Record
Other Related Research

Authors:: Grebien, Florian; Hantschel, Oliver; Wojcik, John; Kaupe, Ines; Kovacic, Boris; Wyrzucki, Arkadiusz M.; Gish, Gerald D.; Cerny-Reiterer, Sabine; Koide, Akiko; Beug, Hartmut; Pawson, Tony; Valent, Peter; Koide, Shohei; Superti-Furga, Giulio

Publication Date:: Sat Oct 01 00:00:00 EDT 2011

Sponsoring Org.:: USDOE

OSTI Identifier:: 1197999

Grant/Contract Number:: AC02-06CH11357

Resource Type:: Published Article

Journal Name:: Cell

Additional Journal Information:: Journal Name: Cell Journal Volume: 147 Journal Issue: 2; Journal ID: ISSN 0092-8674

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Citation Formats


                    Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, and Superti-Furga, Giulio. Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis.  United States: N. p., 2011. 
Web.  doi:10.1016/j.cell.2011.08.046.

Copy to clipboard


                    Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, & Superti-Furga, Giulio. Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis.  United States.  https://doi.org/10.1016/j.cell.2011.08.046

Copy to clipboard


                    Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, and Superti-Furga, Giulio. Sat .  
"Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis".  United States.  https://doi.org/10.1016/j.cell.2011.08.046.

Copy to clipboard


                    
@article{osti_1197999,

  title        = {Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis},

  author       = {Grebien, Florian and Hantschel, Oliver and Wojcik, John and Kaupe, Ines and Kovacic, Boris and Wyrzucki, Arkadiusz M. and Gish, Gerald D. and Cerny-Reiterer, Sabine and Koide, Akiko and Beug, Hartmut and Pawson, Tony and Valent, Peter and Koide, Shohei and Superti-Furga, Giulio},

  abstractNote = {},

  doi          = {10.1016/j.cell.2011.08.046},

  journal      = {Cell},

  number       = 2,

  volume       = 147,

  place        = {United States},

  year         = {Sat Oct 01 00:00:00 EDT 2011},

  month        = {Sat Oct 01 00:00:00 EDT 2011}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1016/j.cell.2011.08.046

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 98 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Journal Article Grebien, Florian ; Hantschel, Oliver ; Wojcik, John ; ... - Cell

Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI) imatinib. However, emerging TKI resistance prevents complete cure. Therefore, alternative strategies targeting regulatory modules of Bcr-Abl in addition to the kinase active site are strongly desirable. Here, we show that an intramolecular interaction between the SH2 and kinase domains in Bcr-Abl is both necessary and sufficient for high catalytic activity of the enzyme. Disruption of this interface led to inhibition of downstream events critical for CML signaling and, importantly, completely abolished leukemia formation in mice. Furthermore, disruption of themore »« less
https://doi.org/10.1016/j.cell.2011.08.046
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

Journal Article Wojcik, John ; Lamontanara, Allan Joaquim ; Grabe, Grzegorz ; ... - Journal of Biological Chemistry

Bcr-Abl is a constitutively active kinase that causes chronic myelogenous leukemia. We have shown that a tandem fusion of two designed binding proteins, termed monobodies, directed to the interaction interface between the Src homology 2 (SH2) and kinase domains and to the phosphotyrosine-binding site of the SH2 domain, respectively, inhibits the Bcr-Abl kinase activity. Because the latter monobody inhibits processive phosphorylation by Bcr-Abl and the SH2-kinase interface is occluded in the active kinase, it remained undetermined whether targeting the SH2-kinase interface alone was sufficient for Bcr-Abl inhibition. To address this question, we generated new, higher affinity monobodies with single nanomolarmore »« less
Cited by 24
https://doi.org/10.1074/jbc.M115.707901

Full Text Available
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells

Journal Article Kato, Yu ; Division of Chemotherapy, Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen, Minato-ku, Tokyo, 105-8512 ; Kunimasa, Kazuhiro ; ... - Biochemical and Biophysical Research Communications

Highlights: • BCR-ABL inhibitors prevent activation of PERK and GCN2. • BCR-ABL inhibitors suppress ATF4 induction, possibly through multiple mechanisms. • Metabolic stress conditions enhance apoptosis induction by BCR-ABL inhibitors. The integrated stress response (ISR) is a cellular process that is characterized by activation of eukaryotic initiation factor (eIF)2α kinases and subsequent induction of activating transcription factor (ATF)4. The ISR plays an important role in protecting cells from tumor-related metabolic stresses, such as nutrient deprivation and perturbed proteostasis. Here, we showed that disruption of the ISR, together with increased cellular stress vulnerability, was produced by pharmacological inhibition of BCR-ABL, themore »« less
https://doi.org/10.1016/J.BBRC.2018.09.032
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells

Journal Article Liu, Zhen ; Zheng, Wenlong ; Liu, Yuan ; ... - Experimental Cell Research

The resistance to tyrosine kinase inhibitors is currently a major problem for chronic myeloid leukemia (CML) treatment and HSPA8 is highly expressed and a hallmark of poor prognosis in several human cancers. However, its role in imatinib-resistant CML (IR-CML) cells remains undetermined. Here, we determined HSPA8 was overexpressed in IR-CML cells and associated with imatinib resistance. HSPA8 ablation could downregulate BCR-ABL/STAT5 and BCR-ABL/AKT signaling pathways, dramatically induce proliferation inhibition, autophagy, G0/G1 phase cell cycle arrest but not apoptosis in IR-CML cells. Significantly, HSPA8 ablation enhanced the antitumor activity of imatinib via promoting apoptosis in vitro and vivo. These findings unraveledmore »« less
https://doi.org/10.1016/J.YEXCR.2021.112708
Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains

Journal Article Sha, Fern ; Gencer, Emel Basak ; Georgeon, Sandrine ; ... - Proc. Natl. Acad. Sci. USA
https://doi.org/10.1073/pnas.1303640110

Similar Records